This study investigates the anti-tumor efficacy of Helicobacter pylori neutrophil-activating protein (HP-NAP) in a mouse model with urothelial tumors. By modulating the immune response, HP-NAP enhances the differentiation of T lymphocytes, leading to tumor cell death.
Begin with an anesthetized female mouse in a supine position, bearing urothelial tumors in its bladder epithelium.
Secure the hind legs, locate the urethral opening, and insert a catheter into the mouse's bladder. Wash the bladder to remove urine.
Inject Helicobacter pylori neutrophil-activating protein, or HP-NAP — an immunomodulatory bacterial protein.
In the tumor microenvironment, HP-NAP interacts with Toll-like receptors on neutrophils and initiates a signaling cascade, increasing proinflammatory cytokine expression.
The cytokines trigger the differentiation of naÏve T lymphocytes into type 1 T helper, or Th1, and type 1 cytotoxic, or Tc1, lymphocytes that produce interferon-gamma.
Interferon-gamma inhibits new blood vessel formation, limiting nutrient and oxygen availability to the tumor.
Additionally, it upregulates tumor-antigen-presenting MHC molecules on the tumor cells, facilitating interaction with Tc1 cells.
This interaction results in the release of cytotoxic molecules that induce tumor cell death, demonstrating the anti-tumor efficacy of HP-NAP.
At least three days after injecting the MB-49 cells, after anesthetizing the animal, catheterize as just demonstrated and using a 1-milliliter syringe with 200 to 300 microliters of sterile PBS, wash the residual urine from the bladder, aspirating all the liquid.
Inject 50 micrograms of Helicobacter pylori neutrophil-activating protein or HPNAP, per 150 microliters of PBS into the bladder, leaving the syringe attached to the catheter to avoid leakage. After an hour, gently remove the catheter from the urethra and place the mouse in a cage under a heating lamp until it awakens.
繁體中文
